XM does not provide services to residents of the United States of America.
A
A

ACADIA


News

U.S. Carnival, FedEx, Micron Technology

U.S. RESEARCH ROUNDUP-Carnival, FedEx, Micron Technology June 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Carnival, FedEx and Micron Technology, on Thursday. HIGHLIGHTS * Carnival Corp CCL.N : Macquarie raises target price to $25 from $24 * FedEx Corp FDX.N : Daiwa Capital Markets raises target price to $318 from $296 * Micron Technology Inc MU.O : JP Morgan raises target price to $180 from $130 * Unifirst Cor
A
E
G
H
H
M
N
S
A
C
C
E

ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule

BRIEF-ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule May 17 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O : ACADIA PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: ID:nBwGllvXa Further company coverage: ACAD.O
A

U.S. Cerence, Epam Systems, Progyny

U.S. RESEARCH ROUNDUP- Cerence, Epam Systems, Progyny May 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cerence, Epam Systems and Progyny, on Friday. HIGHLIGHTS * Cerence Inc CRNC.O : Wells Fargo cuts to equal weight from overweight * Epam Systems Inc EPAM.N : Scotiabank cuts to sector perform from sector outperform * Progyny Inc PGNY.O : KeyBanc cuts to sector weight from overweight * Rapt Therapeutics Inc RAPT
A
C
F
L
C
I

U.S. Crescent Energy, Rockwell Automation, Transdigm Group

U.S. RESEARCH ROUNDUP-Crescent Energy, Rockwell Automation, Transdigm Group May 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Crescent Energy, Rockwell Automation and Transdigm Group, on Thursday. HIGHLIGHTS * Crescent Energy Co CRGY.N : Gerdes Energy Research cuts to neutral from buy * Hubspot Inc HUBS.N : Barclays cuts target price to $575 from $600 * Rockwell Automation Inc ROK.N : Daiwa Capital Markets cuts P
A
A
B
K
M
E
T
A
A
B

Australia's Neuren Pharmaceuticals tumbles on weak sales from US drug licensee

BUZZ-Australia's Neuren Pharmaceuticals tumbles on weak sales from US drug licensee ** Shares of Neuren Pharmaceuticals NEU.AX fall as much as 10.6% to A$17.970, their lowest since Dec. 13, 2023 ** Stock posts its biggest intraday percentage decline since Feb. 28 ** Brain disorder drug maker says quarterly sales of co's drug licensed to U.S.-based
A

Acadia Pharmaceuticals Q1 EPS USD 0.1 Vs. IBES Estimate USD 0.05

BRIEF-Acadia Pharmaceuticals Q1 EPS USD 0.1 Vs. IBES Estimate USD 0.05 May 08 (Reuters) - Acadia Pharmaceuticals Q1 operating expenses USD 190.621 million. Q1 product sales USD 205.831 million vs. IBES estimate USD 208.3 million Q1 net income USD 16.555 million vs. IBES estimate USD 9.5 million Q1 pretax profit USD 21.002 million vs. IBES estimate
A

ACADIA Pharmaceuticals Inc <ACAD.OQ> expected to post earnings of 5 cents a share - Earnings Preview

ACADIA Pharmaceuticals Inc expected to post earnings of 5 cents a share - Earnings Preview ACADIA Pharmaceuticals Inc ACAD.OQ ACAD.O is expected to show a rise in quarterly revenue when it reports results on May 8 for the period ending March 31 2024 The San Diego California-based company is expected to report a 75.8% increase in revenue to $208.292 million from $118.46 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
A

U.S. Domino's Pizza, HCA Healthcare, WW Grainger

U.S. RESEARCH ROUNDUP-Domino's Pizza, HCA Healthcare, WW Grainger April 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Domino's Pizza, HCA Healthcare and WW Grainger, on Tuesday. HIGHLIGHTS * Domino's Pizza Inc DPZ.N : BTIG raises target price to $580 from $515 * HCA Healthcare Inc HCA.N : TD Cowen cuts target price to $360 from $371 * Molina Healthcare Inc MOH.N : TD Cowen cuts target price to $412 from $453 * W
A
C
C
X
O
A
H
W
E
U

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission Has Been Accepted For Filing And Priority Review By Health Canada

BRIEF-Acadia Pharmaceuticals Announces Trofinetide New Drug Submission Has Been Accepted For Filing And Priority Review By Health Canada April 22 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O : ACADIA PHARMACEUTICALS ANNOUNCES TROFINETIDE NEW DRUG SUBMISSION FOR TREATMENT OF RETT SYNDROME HAS BEEN ACCEPTED FOR FILING AND PRIORITY REVIEW BY HEALTH C
A

U.S. Apollo, Tesla, UDR

U.S. RESEARCH ROUNDUP-Apollo, Tesla, UDR April 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apollo, Tesla and UDR, on Wednesday. HIGHLIGHTS * Apollo APO.N : Jefferies raises target price to $119 from $112 * Blackstone Inc BX.N : Piper Sandler cuts target price to $146 from $150 * Pfizer Inc PFE.N : Berenberg cuts target price to $27 from $29 * Tesla Inc TSLA.O : Jefferies cuts target price to $165 from $185 * U
A
T
S
A
A
L



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.